DK1089998T3 - Epothilon-derivater samt deres syntese og anvendelse - Google Patents
Epothilon-derivater samt deres syntese og anvendelseInfo
- Publication number
- DK1089998T3 DK1089998T3 DK99931120T DK99931120T DK1089998T3 DK 1089998 T3 DK1089998 T3 DK 1089998T3 DK 99931120 T DK99931120 T DK 99931120T DK 99931120 T DK99931120 T DK 99931120T DK 1089998 T3 DK1089998 T3 DK 1089998T3
- Authority
- DK
- Denmark
- Prior art keywords
- absent
- single bond
- synthesis
- alkyl
- double bond
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 150000003883 epothilone derivatives Chemical class 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229930013356 epothilone Natural products 0.000 abstract 1
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 abstract 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Silicon Polymers (AREA)
- Plural Heterocyclic Compounds (AREA)
- Lubricants (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/102,602 US6380394B1 (en) | 1996-12-13 | 1998-06-22 | Epothilone analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1089998T3 true DK1089998T3 (da) | 2007-01-15 |
Family
ID=22290705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99931120T DK1089998T3 (da) | 1998-06-22 | 1999-06-21 | Epothilon-derivater samt deres syntese og anvendelse |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US6380394B1 (enExample) |
| EP (2) | EP1741715A1 (enExample) |
| JP (1) | JP4681732B2 (enExample) |
| KR (3) | KR20080045298A (enExample) |
| CN (1) | CN1192031C (enExample) |
| AT (1) | ATE343573T1 (enExample) |
| AU (1) | AU757854B2 (enExample) |
| BR (1) | BR9911420A (enExample) |
| CA (1) | CA2334342C (enExample) |
| CY (1) | CY1105863T1 (enExample) |
| CZ (1) | CZ301783B6 (enExample) |
| DE (1) | DE69933767T2 (enExample) |
| DK (1) | DK1089998T3 (enExample) |
| ES (1) | ES2273502T3 (enExample) |
| HU (1) | HUP0102711A3 (enExample) |
| ID (1) | ID28210A (enExample) |
| IL (3) | IL139784A0 (enExample) |
| MX (1) | MXPA00012443A (enExample) |
| NO (1) | NO328417B1 (enExample) |
| NZ (1) | NZ508622A (enExample) |
| PL (1) | PL197648B1 (enExample) |
| PT (1) | PT1089998E (enExample) |
| RU (1) | RU2227142C2 (enExample) |
| SK (2) | SK285647B6 (enExample) |
| TR (1) | TR200003844T2 (enExample) |
| WO (1) | WO1999067252A2 (enExample) |
| ZA (1) | ZA200007059B (enExample) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4183099B2 (ja) | 1995-11-17 | 2008-11-19 | ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） | エポチロンｃおよびｄ、製造法ならびに組成物 |
| WO1998022461A1 (de) * | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
| JP4579351B2 (ja) * | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロンの合成とその中間体及びその類似物並びにその使用 |
| US6867305B2 (en) * | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
| DE19820599A1 (de) * | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
| US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
| KR100716272B1 (ko) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
| US6262094B1 (en) * | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
| US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| EP1169038B9 (en) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| WO2001038317A2 (en) * | 1999-11-24 | 2001-05-31 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Fungicidal melithiazole derivatives |
| US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| HUP0302905A3 (en) * | 2000-09-22 | 2006-05-29 | Biotechnolog Forschung Gmbh | Triazolo-epothilone-analogs, process for their preparation and pharmaceutical compositions containing them |
| CA2425828A1 (en) * | 2000-10-13 | 2002-04-18 | The University Of Mississippi | Synthesis of epothilones and related analogs |
| BRPI0206509B8 (pt) | 2001-01-25 | 2021-05-25 | R Pharm Us Operating Llc | processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer |
| JP2004521122A (ja) | 2001-01-25 | 2004-07-15 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン類似体の非経口製剤 |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| CA2438610A1 (en) | 2001-02-20 | 2002-08-29 | Francis Y. F. Lee | Treatment of refractory tumors using epothilone derivatives |
| MXPA03007423A (es) | 2001-02-20 | 2003-11-18 | Bristol Myers Squibb Co | Derivados de epotilona para tratamiento de tumores refractarios. |
| HUP0303895A3 (en) * | 2001-02-27 | 2007-06-28 | Biotechnolog Forschung Gmbh | Degradation of epothilones |
| CZ305799B6 (cs) | 2001-03-14 | 2016-03-23 | Bristol-Myers Squibb Company | Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí |
| EP1392664A4 (en) * | 2001-06-01 | 2005-01-26 | Bristol Myers Squibb Co | EPOTHILONE DERIVATIVES |
| WO2003018002A2 (en) * | 2001-08-23 | 2003-03-06 | Novartis Ag | Cyclopropyl and cyclobutyl epothilone analogs |
| WO2003026744A1 (en) * | 2001-09-25 | 2003-04-03 | Alcon, Inc. | The use of epothilones and analogs in conjunction with ophthalmic surgery |
| DE60224299T2 (de) * | 2001-10-25 | 2008-12-11 | Novartis Ag | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor |
| US20050227300A1 (en) * | 2001-12-07 | 2005-10-13 | Atadja Peter W | Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors |
| TWI341728B (en) | 2002-01-14 | 2011-05-11 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
| TW200303202A (en) * | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
| EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
| ATE452896T1 (de) * | 2002-03-12 | 2010-01-15 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
| WO2003077903A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| ES2297189T3 (es) * | 2002-08-02 | 2008-05-01 | Novartis Ag | Derivados de epotilona. |
| US7384964B2 (en) * | 2002-08-23 | 2008-06-10 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| CA2496477C (en) * | 2002-08-23 | 2012-10-16 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| GB0221312D0 (en) * | 2002-09-13 | 2002-10-23 | Novartis Ag | Organic compounds |
| WO2004026254A2 (en) | 2002-09-23 | 2004-04-01 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
| WO2004035050A1 (en) * | 2002-10-15 | 2004-04-29 | Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College | Use of epothilone derivatives for the treatment of hyperparathyroidism |
| EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| EP1559447A1 (en) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
| US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| GB0405898D0 (en) * | 2004-03-16 | 2004-04-21 | Novartis Ag | Organic compounds |
| US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| JP2008536479A (ja) | 2005-02-11 | 2008-09-11 | ユニバーシティ オブ サザン カリフォルニア | ジスルフィド架橋を有するタンパク質の発現法 |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| US7893268B2 (en) * | 2005-07-27 | 2011-02-22 | University Of Toledo | Epithiolone analogues |
| WO2007062288A2 (en) * | 2005-11-22 | 2007-05-31 | The Scripps Research Institute | Chemical synthesis of a highly potent epothilone |
| US7653731B2 (en) * | 2006-02-24 | 2010-01-26 | Microsoft Corporation | Management of connections to external data |
| US8008256B2 (en) * | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
| MY159563A (en) | 2006-05-16 | 2017-01-13 | Pharmascience Inc | Iap bir domain binding compounds |
| WO2008070672A2 (en) | 2006-12-04 | 2008-06-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and cpg rich dna |
| CA2677803A1 (en) | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
| WO2008118327A1 (en) * | 2007-03-23 | 2008-10-02 | University Of Toledo | Conformationally restrained epothilone analogues as anti-leukemic agents |
| EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
| EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
| DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
| KR20110043653A (ko) * | 2008-07-03 | 2011-04-27 | 파르마 마르 에스.에이. | 항종양 마크롤라이드 |
| US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
| KR20120140658A (ko) | 2010-02-12 | 2012-12-31 | 파마사이언스 인크. | Ｉａｐ ｂｉｒ 도메인 결합 화합물 |
| US20110300150A1 (en) | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
| WO2012100206A2 (en) | 2011-01-20 | 2012-07-26 | Board Of Regents, The University Of Texas System | Mri markers, delivery and extraction systems, and methods of manufacture and use thereof |
| CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
| CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
| WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
| US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
| EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| CN104768962B (zh) | 2012-11-17 | 2017-04-05 | 北京市丰硕维康技术开发有限责任公司 | 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物 |
| WO2014116594A1 (en) * | 2013-01-23 | 2014-07-31 | The University Of Toledo | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| AU2014283185B2 (en) | 2013-06-21 | 2019-05-02 | Araris Biotech Ltd. | Enzymatic conjugation of polypeptides |
| CA3002027A1 (en) * | 2015-10-16 | 2017-04-20 | William Marsh Rice University | Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW221441B (enExample) * | 1991-01-25 | 1994-03-01 | Taiho Pharmaceutical Co Ltd | |
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| JP4183099B2 (ja) | 1995-11-17 | 2008-11-19 | ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） | エポチロンｃおよびｄ、製造法ならびに組成物 |
| AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
| WO1998022461A1 (de) | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
| JP4579351B2 (ja) | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロンの合成とその中間体及びその類似物並びにその使用 |
| US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| NZ337195A (en) | 1997-02-25 | 2001-05-25 | Biotechnolog Forschung Gmbh | Epothilones with a modified side chain |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| DK1005465T3 (da) | 1997-08-09 | 2007-11-05 | Bayer Schering Pharma Ag | Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse |
| DE19744135C1 (de) | 1997-09-29 | 1999-03-25 | Schering Ag | Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe |
-
1998
- 1998-06-22 US US09/102,602 patent/US6380394B1/en not_active Expired - Fee Related
-
1999
- 1999-06-21 SK SK1971-2000A patent/SK285647B6/sk not_active IP Right Cessation
- 1999-06-21 KR KR1020087011102A patent/KR20080045298A/ko not_active Ceased
- 1999-06-21 TR TR2000/03844T patent/TR200003844T2/xx unknown
- 1999-06-21 CN CNB998077690A patent/CN1192031C/zh not_active Expired - Fee Related
- 1999-06-21 AT AT99931120T patent/ATE343573T1/de active
- 1999-06-21 BR BR9911420-8A patent/BR9911420A/pt not_active Application Discontinuation
- 1999-06-21 PT PT99931120T patent/PT1089998E/pt unknown
- 1999-06-21 US US09/720,070 patent/US6531497B1/en not_active Expired - Fee Related
- 1999-06-21 AU AU47748/99A patent/AU757854B2/en not_active Ceased
- 1999-06-21 NZ NZ508622A patent/NZ508622A/en not_active IP Right Cessation
- 1999-06-21 WO PCT/EP1999/004287 patent/WO1999067252A2/en not_active Ceased
- 1999-06-21 CA CA2334342A patent/CA2334342C/en not_active Expired - Fee Related
- 1999-06-21 KR KR1020007014546A patent/KR100864742B1/ko not_active Expired - Fee Related
- 1999-06-21 KR KR1020097010651A patent/KR20090066332A/ko not_active Ceased
- 1999-06-21 EP EP06118853A patent/EP1741715A1/en not_active Ceased
- 1999-06-21 DE DE69933767T patent/DE69933767T2/de not_active Expired - Lifetime
- 1999-06-21 EP EP99931120A patent/EP1089998B1/en not_active Expired - Lifetime
- 1999-06-21 HU HU0102711A patent/HUP0102711A3/hu unknown
- 1999-06-21 MX MXPA00012443A patent/MXPA00012443A/es not_active IP Right Cessation
- 1999-06-21 JP JP2000555904A patent/JP4681732B2/ja not_active Expired - Fee Related
- 1999-06-21 IL IL13978499A patent/IL139784A0/xx unknown
- 1999-06-21 DK DK99931120T patent/DK1089998T3/da active
- 1999-06-21 SK SK5009-2007A patent/SK287864B6/sk not_active IP Right Cessation
- 1999-06-21 CZ CZ20004769A patent/CZ301783B6/cs not_active IP Right Cessation
- 1999-06-21 RU RU2000132188/04A patent/RU2227142C2/ru not_active IP Right Cessation
- 1999-06-21 PL PL345327A patent/PL197648B1/pl not_active IP Right Cessation
- 1999-06-21 ES ES99931120T patent/ES2273502T3/es not_active Expired - Lifetime
- 1999-06-21 ID IDW20002739A patent/ID28210A/id unknown
-
2000
- 2000-11-20 IL IL139784A patent/IL139784A/en not_active IP Right Cessation
- 2000-11-30 ZA ZA200007059A patent/ZA200007059B/en unknown
- 2000-12-14 NO NO20006378A patent/NO328417B1/no not_active IP Right Cessation
-
2003
- 2003-03-11 US US10/386,999 patent/US7579366B2/en not_active Expired - Fee Related
-
2006
- 2006-12-20 CY CY20061101818T patent/CY1105863T1/el unknown
-
2007
- 2007-04-23 IL IL182744A patent/IL182744A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1089998T3 (da) | Epothilon-derivater samt deres syntese og anvendelse | |
| LU91210I2 (fr) | Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER) | |
| ATE250573T1 (de) | Azetidin- und pyrrolidinderivate | |
| ATE125539T1 (de) | 1,4-benzothiazedinderivat. | |
| DE69907331D1 (de) | Fungizide Zusammensetzung enthaltend ein 1,2,3-Thiadiazolderivat sowie deren Verwendung | |
| AU689304B2 (en) | Quinazoline derivative | |
| ATE134364T1 (de) | Phenylthioharnstoffderivate und ihre pharmazeutische verwendung | |
| FI852223L (fi) | Saosom fungicider anvaenda triazoler. | |
| LV10076A (lv) | Aizvietoti beta- diketoni | |
| PL352613A1 (en) | Derivatives of benzamide, insecticides for agriculture and horticulture as well as their application | |
| NO175253C (no) | Forbindelse, anvendelse og preparat | |
| NO921282D0 (no) | Benzotiazolderivater og deres anvendelse | |
| ATE105565T1 (de) | Pradimicinderivate. | |
| DK0641794T3 (da) | Thienyl- og furylpyrrolderivater, deres fremstilling samt deres anvendelse som insecticider og acaricider | |
| MX174310B (es) | Control de microorganismos en plantas con 1-hidroximetilpirazoles | |
| DK0745680T3 (da) | Nye fungicide midler LL-15G256 gamma, delta, og epsilon produceret af LL-15G256 (Hypoxylon oceanicum) |